Torrent Pharmaceuticals Limited engages in the research, development, manufacturing, and marketing of generic pharmaceutical formulations in India, the United States, Germany, Brazil, and internationally. It offers products in various therapeutic areas, including cardiovascular, central nervous system, gastrointestinal, women healthcare, diabetology, pain management, gynecology, oncology, and anti-infective, as well as provides vitamins, minerals, and nutrients. The company also provides contract manufacturing services. It has licensing collaborations of Baricitinib, Molnupiravir, and Paxlovid for its Covid portfolio. Torrent Pharmaceuticals Limited was formerly known as Trinity Laboratories and changed its name to Torrent Pharmaceuticals Limited in 1971. The company was founded in 1959 and is based in Ahmedabad, India. Torrent Pharmaceuticals Limited is a subsidiary of Torrent Investments Private Limited.
Revenue of Torrent Pharmaceuticals Limited (TORNTPHARM.NS)
Revenue in 2023 (TTM): $1.25 B
According to Torrent Pharmaceuticals Limited's latest financial reports the company's current revenue (TTM) is $1.25 B. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Torrent Pharmaceuticals Limited
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $1.25 B | $551.4 M | $412.86 M | $277.38 M | $195.33 M |
| 2022 | $1.12 B | $793.54 M | $339.94 M | $217.81 M | $146.85 M |
| 2021 | $992.81 M | $693.57 M | $252.71 M | $144.57 M | $91.65 M |
| 2020 | $930.01 M | $666.4 M | $299.13 M | $179.99 M | $147.63 M |
| 2019 | $917.48 M | $651.85 M | $269.91 M | $139.93 M | $120.84 M |
| 2018 | $879.96 M | $606.17 M | $198.1 M | $66.24 M | $51.45 M |
| 2017 | $690.74 M | $481.2 M | $195.25 M | $109.79 M | $79.97 M |
| 2016 | $668.91 M | $446.19 M | $187.37 M | $128.32 M | $110.09 M |
| 2015 | $768.82 M | $574.48 M | $326.08 M | $278.76 M | $203.12 M |
| 2014 | $539.97 M | $366.08 M | $120.32 M | $110.83 M | $88.56 M |
| 2013 | $475.52 M | $322.16 M | $128.21 M | $99.53 M | $78.29 M |
| 2012 | $359.51 M | $245.36 M | $82.32 M | $68.59 M | $51.03 M |
| 2011 | $305.95 M | $190.23 M | $56.58 M | $42.29 M | $33.5 M |
| 2010 | $250.24 M | $168.1 M | $52.35 M | $40.41 M | $31.86 M |
| 2009 | $225.95 M | $158.62 M | $50.69 M | $40.95 M | $27.26 M |
| 2008 | $192.3 M | $129.18 M | $31.88 M | $22.66 M | $21.74 M |
| 2007 | $159.77 M | $122 M | $24.48 M | $17.58 M | $15.88 M |
| 2006 | $153.16 M | $99.68 M | $18.65 M | $12.86 M | $11.03 M |
| 2005 | $114.06 M | $71.04 M | $13.04 M | $9.16 M | $6 M |
| 2004 | $64.6 M | $41.83 M | $9.36 M | $6.71 M | $5.75 M |